Laboratory Equipment Market from Key End-use Sectors to Surge in the Near Future 2027

 Market Forecast

Global Laboratory Equipment Market is expected to hold a value of USD 58,960 Million by 2025 at a CAGR of 7.3%.

Market Synopsis

There has been a high level of technological improvement in laboratory equipment in the past few years, which is fueling the global market growth. Also, as laboratory equipment is used rigorously for testing and research purposes, companies are investing in this market.

Market Influencer

The increasing initiatives by public and private companies boost market growth. The growing number of clearances and product launches by key players in the market are likely to act as a promising factor for the growth in the near future.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8365 

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to be the largest market owing to the rising per capita healthcare expenditure. The laboratory equipment market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European laboratory equipment market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The laboratory equipment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the increasing clinical laboratories and increasing pool of patient population, the market in Asia-Pacific is expected to be the fastest-growing. The laboratory equipment market in the Middle East & Africa has been divided into the Middle East and Africa.

Segmentation

The global laboratory equipment market has been segmented based on product type, application, and end user.

The market, based on product type, has been divided into incubators, centrifuges, spectrometers, scopes, sonicators, autoclaves, and others. The incubators segment is likely to be the largest during the review period due to the growing use of this device in various areas of testing. The spectrometers segment is predicted to be the fastest-growing due to the increasing product launches in the market. For instance, in April 2018, Bruker launched INVENIO Fourier Transform Infrared (FT-IR) research spectrometer.

The global laboratory equipment market has been segmented, on the basis of application, into biochemistry, endocrinology, microbiology, hematology, genetic testing, and others. The biochemistry segment is expected to hold the majority share of the market owing to the wide number of biochemical tests carried out in the laboratories. The endocrinology segment is expected to be the fastest-growing due to the rising patient pool, coupled with the increasing number of tests.

The end users of the market are hospitals and clinics, diagnostic centers, and others. The hospitals and clinics segment is expected to hold the largest share of the market due to the increasing number of hospitals and clinics using laboratory equipment. The diagnostic centers segment is expected to be the fastest-growing owing to the increased preference of medical professionals for carrying out diagnostic tests.

Key Players

Some of the key players in the global laboratory equipment market are Agilent Technologies, Inc. (US), BD (US), Beckman Coulter, Inc. (US), Bio-Rad Laboratories, Inc. (US), Bruker (US), Eppendorf AG (Germany), F. Hoffmann LA-Roche AG (Switzerland), PerkinElmer Inc. (US), Shimadzu Corporation (Japan), Thermo Fisher Scientific Inc. (US), and Waters (US), among others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/laboratory-equipment-market-8365 

Hearing Aids Market to Witness Increase in Revenues by 2020-2027

 Market Highlights

According to MRFR analysis, the global hearing aids market is expected to register a CAGR of ~7% during the forecast period of 2019 to 2025 and was valued at USD 8 billion in 2018.

A hearing aid is an electronic device which amplifies sound so that a person with hearing loss can listen, participate in daily activities, and communicate with others. The three basic parts of a hearing aid are a speaker, an amplifier, and a microphone.

The growth of global hearing aids market is driven by various factors such as increasing incidence of hearing loss, the launch of new products, increasing geriatric population, and raising awareness about hearing loss treatment. However, the low penetration of hearing aids and product recalls are expected to curb the growth of the global hearing aids market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8364 

The global hearing aids market is currently dominated by several market players. The key players are involved in product launches and strategic collaborations to strengthen their market positions.

Regional Analysis

The market has been divided, by region, into Europe, the Americas, Asia-Pacific, and the Middle East & Africa. Europe is expected to be the largest market owing to the rising incidence of hearing loss and sophisticated healthcare infrastructure. The European hearing aids market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The Americas holds the second largest market share. The hearing aids market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The hearing aids market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the increasing awareness regarding the use of hearing aids and increasing population affected by hearing disorders, the market in Asia-Pacific is expected to be the fastest-growing. The hearing aids market in the Middle East & Africa has been divided into the Middle East and Africa and is expected to hold the least market share.

Segmentation

The global hearing aids market has been segmented based on product, product type, type of hearing loss, technology type, and distribution channel.

The market, based on product, has been divided into devices, implants, and accessories, out of which implants is the fastest-growing segment. For instance, the Australia-based manufacturer Cochlear Ltd reported a profit of USD 265 to USD 275 million in first quarter of 2019, 8% to 12% more as compared to that in the first quarter of 2018.

The global hearing aids market has been segmented, on the basis of product type, into wired and wireless. Wireless is the fastest-growing segment owing to technological advancements and product launches. For instance, Sonova, in November 2018 launched products based on SWORD (Sonova Wireless One Radio Digital) chip. The new technology allows hearing instruments to connect with electronic devices such as televisions or mobile phones.

The type of hearing loss segments of the market are sensorineural, conductive, and others. The growth of the segment is due to the high prevalence of hearing loss. For instance, in 2018, around 2 to 3 out of 1000, children in the US are born with a hearing loss in one or both ears.

The technology type segment of the market is segmented as digital hearing aids and analog hearing aids. The digital hearing aids segment is expected to be both, the largest shareholder and the fastest-growing segment owing to its advantages over analog counterparts.

The distribution channel segment is classified into retail stores, E-commerce, and others. The E-commerce segment is expected to be the fastest-growing segment owing to ease of access to products for customers.

Key Players

Some of the key players in the global hearing aids market are Sonova (Switzerland), Cochlear Ltd. (Australia), GN Store Nord A/S (Denmark), Sivantos Pte. Ltd. (Singapore), Arphi Electronics Private Limited (India), Demant A/S (Denmark), Starkey (US), WIDEX INDIA PRIVATE LIMITED (Denmark), Zounds Hearing (US), SeboTek Hearing Systems, LLC (US), Audina Hearing Instruments, Inc. (US), and Microson (Spain).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/hearing-aids-market-8364 

Desalting and Buffer Exchange Market Detailed Industry Report Analysis 2020-2027

 The Global Desalting and Buffer Exchange Market is expected to grow significantly over the forecast period. It is anticipated that the market held a market value of USD 615.20 million in 2017 and is projected to grow at a CAGR of 10.5% over the forecast period. Desalting is a separation process removes soluble low molecular weight substances from protein and nucleic acid samples. Buffer exchange is the replacement of one set of buffer salts with another set.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6633

Additionally, during the preparation of biological samples, buffer exchange is an essential step, as it prepares the sample for downstream applications. The factors such as growing demand for monoclonal antibodies, increasing research and development expenditure by the biopharmaceutical companies, and growing focus on proteomic and genomic research is expected to drive the market growth over the forecast period.  According to the Office for National Statistics, gross domestic expenditure on R&D was Euro 33.1 billion (USD 35.2 billion) in 2016. Despite the drivers, the lack of skilled professionals is expected to restrain the market growth.

Segmentation

The Global Desalting and Buffer Exchange Market has been segmented into technique, product, and application. On the basis of technique, the market has been segmented into filtration, chromatography, and precipitation. The filtration segment has been further segmented into ultrafiltration and dialysis. The chromatography segment has been segmented into size-exclusion chromatography and others.

The market, by product, has been segmented into kits, cassettes, filter plates, spin columns, membrane filters, and others.

The market, by application, has been segmented into bioprocess applications and diagnostic applications. The bioprocess segment is expected to account for the largest market share in 2017. The market growth of the segment is attributed to the increasing demand for biopharmaceutical products.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The desalting and buffer exchange market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European desalting and buffer exchange market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The desalting and buffer exchange market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The desalting and buffer exchange market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key Players

Merck KGaA, GE Healthcare, Sartorius AG, Thermo Fisher Scientific, Danaher Corporation, Agilent Technologies, Inc., Bio-Rad Laboratories, Avantor, Repligen Corporation, Bio-works Technologies Ab, Phynexus, Inc., and Norgen Biotek Corp. are some of the key players in the global desalting and buffer exchange market.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/desalting-and-buffer-exchange-market-6633

Bleeding Disorders Treatment Market Foraying into Emerging Economies 2020-2027

 The Global Bleeding Disorders Treatment Market is expected to register a growth of significant CAGR 10.0% during the forecast period (2018–2023).

A bleeding disorder is a condition where there is a problem with the body’s clotting method. This disorder leads to heavy and protracted bleeding after an injury. The bleeding process can also start on its own. Most of the types of bleeding disorders are hereditary but some are acquired due to liver diseases, side effects of certain medications, low red blood cell count, vitamin K deficiency and others. The global bleeding disorders treatment market is expected to witness fast growth during the forecast period due to growth in the number of people suffering from liver diseases, anemia, and other blood coagulation disorders.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6592

The global bleeding disorders treatment market is seeing a rise due to growth in the number of diagnosed patients with bleeding disorders, rising research and development activities and investments by key players growth in awareness about bleeding disorders especially hemophilia and positive government initiatives in the developed countries towards establishing a wide network of diagnosis and treatment centers complementing the market growth. However, the absence of access to proper treatment due to the high cost of medication and the shortage of skilled health professionals hinders the growth of the market.

Segmentation

The global bleeding disorders treatment market has been segmented on the basis of type, drug class, treatment and end users.

On the basis of type, the market has been classified as hemophilia A, hemophilia B, Von Willebrand Disease (vWD) and others.

On the basis of drug class, the market has been classified as plasma-derived coagulation factor concentrates market, global recombinant coagulation factor concentrate market, global others bleeding disorders treatment market.

On the basis of treatment, the market has been classified as desmopressin (DDAVP), hormone replacement therapy, contraceptives, anti-fibrinolytic/clot-stabilizing drugs, fibrin sealants, drugs applied to cuts and pipeline analysis (phase I, phase II and phase III clinical trials)

On the basis of end users, the market has been classified as hospitals, clinics, specialty clinics, research institutes, and others.

On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.

The European bleeding disorders treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The bleeding disorders treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The bleeding disorders treatment market in the Middle East and Africa has been segmented into the Middle East and Africa.

Regional Market Summary

In the bleeding disorders treatment market, North America is anticipated to account for largest market share due to the early adoption of advanced medical technologies, continuous development by companies operating into drugs. According to the Hemophilia Federation of America, around 20,000 people are affected by hemophilia and approximately 1% of the population is suffering from Von Willebrand Disease (VWD).

The European market is expected to hold the second largest market share. Factors such as a rise in research expenses, advancement of technology, the decline in human health, and the necessity for innovative and effective therapies boost the growth of the market in this region. According to Statista, around 149,764 people were diagnosed with hemophilia A and about 10,811 people were diagnosed with other platelet disorders in the year 2016.

Whereas the market share in Asia-Pacific region is also anticipated to experience growth in the near future due to access to optimal treatment facilities and growing demand for increasing government initiatives, advanced technology, better adoption rate, and rising healthcare expenditure. According to the annual report survey of 2015 by the World Federation of Hemophilia, it is estimated that there were 17,346 million people suffering from hemophilia.

The market in the Middle East & Africa is expected to account for the smallest share of the global bleeding disorders treatment market due to an underdeveloped healthcare sector, the dearth of technical knowledge, and poor medical facilities.

Key Players

Some of the key players in the global bleeding disorders treatment market are Shire Plc, Bayer Pharmaceuticals, Novo Nordisk A/S, Pfizer Inc., Biogen Idec, CSL Behring, Grifols, Octapharma, Sun Pharmaceutical Industries Ltd., BDI Pharma, Ferring Pharmaceuticals, and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/bleeding-disorders-treatment-market-6592

Retinal Implants Market to Witness Increase in Revenues by 2020-2027

 Global Retinal Implants Market likely to exhibit a healthy growth over the next couple of years. Retinal implants have emerged as an innovative technology in the field of ophthalmology. They are being used for improving eyesight of people with partial or complete blindness. The technology is still in its nascent stage hence a mixed speculation continues to hover around it. Investment in retinal implants and prostheses R&D has increased in recent years owing to their immense market potential. Several private eyecare companies have entered the frame and are focusing on introducing more effective retinal implants. Majority of retinal implants that are currently available in the market are aimed at partially restoring useful eye vision. Such implants are effective in treating vision loss caused due to age-related macular degeneration (AMD) and retinitis pigmentosa (RP). Visual devices such as bionic eye and visual prosthesis are expected to have bigger impact in years to come, which in turn will pave the way for retinal implant market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6580

Report Synopsis

This MRFR report offers a thorough analysis of the global retinal implants market. The primary objective of the report is to analyze the current market landscape and its future potential. All the relevant parameters have been considered for market analysis. The report also includes a discussion on the growth opportunities, drivers and restraints. 

Competition Tracking

Philips Healthcare, Retina Implant AG, Second Sight Medical Products, Inc. Bionic Eye Technologies, Inc., Bionic Vision Australia, VisionCare Ophthalmic Technologies, Inc, Abbott Vascular.

The report offers insights into the leading market players and presents an assessment of their current market position. Company information with regards to revenue, segmental share, geographical income, SWOT, growth strategies, new product launch, M&A activities, and the latest R&D initiatives is also available in the report.

Segmentation

The global retinal implants market has been segmented into device type, disease indication, and end user. By device type, the market has been segmented into retina implant alpha AMS, Argus II, implantable miniature telescope, and others.  By disease indication, the market has been segmented into age-related macular degeneration (AMD) and retinitis pigmentosa. By end user, the market has been segmented into multi-specialty hospitals, ophthalmic clinics, and research institutes.

Regional Analysis

North America, Europe, Asia Pacific, and the Rest of the World are the key markets for retinal implants. North America accounts for a substantial share of the global market. Higher availability of the product, improving reimbursement scenario and higher affordability in the region supports the growth of the North America market for retinal implants. Presence of highly skilled surgeons to perform immensely complex surgical procedure also accelerates adoption in the region.

In Europe, the market is driven by an increase in R&D activities and the expansion of clinical trials.

Presence of developing countries such as India, China, and Japan, who outlay massive amounts on healthcare expenditure, coupled with growing disposable income and affordability supports the growth of the market in Asia Pacific.

Rest of the World market is expected to fare well in the coming years since various market players are foraying into the untapped regions to leverage the potential they offer for market expansion.

Research Methodology

Market Research Future (MRFR) employs a multi-layered analysis module for presenting accurate industry outlook. The combination of primary and secondary research processes for analysis of governing factors and macro-economic indicators of the market. Detailed surveys and interviews are conducted with key opinion makers across the value chain for collection of primary data. Secondary research processes are leveraged for verification of collected data through valuable inputs from SEC filings, white paper references, paid databases, research publications and other credible sources available in public domain. Additionally, top-down and bottom-up approaches are utilized to extrapolate data, which is then verified using a powerful data triangulation technique. These comprehensive research methods ensure accuracy and objectivity of the market foresight.

For the scope of the research, MRFR’s report offers a comprehensive segmental analysis of the global market for petroleum coke (fuel-grade)

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/retinal-implants-market-6580

Rhabdomyosarcoma Market – Comparative Analysis by 2027

 The global rhabdomyosarcoma market is expected to grow significantly over the forecast period. It is estimated that the global rhabdomyosarcoma market is expected to register a CAGR ~ 4.8 % during the forecast period of 2018–2023. Rhabdomyosarcoma is a type of cancerous tumor that starts to develop in the soft tissues of the body. Cells affected by rhabdomyosarcoma can grow and spread very fast.

Numerous factors such as raising awareness of rhabdomyosarcoma and its increasing prevalence are expected to drive the growth of the market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6569

Moreover, favorable healthcare investments by government and the rising demand for better treatments boosts the growth of the market. However, stringent government regulation for product approval and huge costs of the treatment may hamper the market growth during the assessment period.

Segmentation

The global rhabdomyosarcoma market has been segmented into type, diagnosis, and treatment.

The market, on the basis of type, has been segmented into Embryonal Rhabdomyosarcoma and Alveolar Rhabdomyosarcoma.

The market, by diagnosis, has been segmented into Imaging Tests and Biopsy.

Imaging tests are further segmented into X-Ray, MRI scan, CT scan, PET scan, and Bone Scan.

Biopsy is further segmented into Needle Biopsy and Surgery Biopsy.

The market, by treatment, has been segmented into Surgery, Radiation Therapy, Chemotherapy and Stem Cell Therapy. Chemotherapy is expected to account for the largest market share due to its effective treatment for minimizing the risk of cancer reoccurrence and high preference among the patients. Radiation therapy is anticipated to be the fastest growing segment due to technological advancements in the segment.

The market, by region, has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The rhabdomyosarcoma market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European rhabdomyosarcoma market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The rhabdomyosarcoma market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The rhabdomyosarcoma market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key players

Boehringer Ingelheim International GmbH, Pfizer Inc, Eli Lilly & Company, Novartis AG, Bristol Myers Squibb Company, TAIHO ONCOLOGY, INC., Oasmia, Bellicum Pharmaceuticals, Inc., CELGENE CORPORATION, Eisai Co., Ltd., MacroGenics, Inc., NantKwest., Tarveda Therapeutics., Exelixis, Inc., and Ipsen Pharma are some of the key players in the global rhabdomyosarcoma market.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/rhabdomyosarcoma-market-6569

Oral Thin Film Drugs Market: Industry Trends and Developments 2020-2027

 Oral thin films (OTF) are an innovative method discovered by pharmaceutical scientists for delivering drugs orally or bucally (absorption or dissolution in the mouth). OTF drugs have gained popularity owing to its rapid dissolution on contact with saliva. The global oral thin film drugs market is predicted to exhibit an 8.10% CAGR from 2019 to 2027 (forecast period), as per the latest report by Market Research Future (MRFR). This can be credited to the expanding geriatric population and their need for advanced drug delivery methods to keep chronic diseases such as diabetes at bay. Continuous investment in research and development (R&D) by companies to create easily dissolvable solutions for other diseases is expected to spur market growth over the forecast period. Introduction of OTF drugs in developing countries can act as a good revenue source for the OTF drugs market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6547

Report Overview

The report provides an accurate overview of the market complete with statistical graphs to support the forecasted figures. Our analysts make insightful predictions regarding the scope of the market and its future prospects. MRFR’s report includes a thorough analysis of the global oral thin film drugs market segmented on the basis of product, disease indication, distribution channel, and region. Numerous growth strategies undertaken by companies as well as the latest trends driving the market are outlined in the report. The market share of all prominent players and their current position is discussed in minute detail. It analyzes new revenue sources for players and emphasizes on the various strategies implemented by players.

Segment Overview

The global oral thin film drugs market is segmented by product, disease indication, and distribution channel. By product, the market is divided into sublingual and fast dissolving buccal film.  By disease indication, the market is segmented into opioid dependence, migraine, schizophrenia, and nausea and vomiting, and others. Distribution channel discussed in the report include hospital pharmacies, retail pharmacies, online drug stores, and others. The segments covered in the oral thin film drugs market report are analyzed with respect to four main regions namely – Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA), with respective country-level market sizing. The report discusses in detail the various players residing in these regions and their respective strategies to climb up the market ladder.

Competitive Landscape

Prominent players in the oral thin film drugs market include Johnson & Johnson Services, Inc. (U.S.), Pfizer Inc. (U.S.), CURE Pharmaceutical (U.S.), Novartis AG (Switzerland), LTS Lohmann Therapie-Systeme AG (Germany), GlaxoSmithKline Plc (U.K.), and Indivior Plc (U.S.).

The report offers a comprehensive analysis on the profiles on these market players and assesses their current standing in the market. Company history coupled with annual turnover, profit margins, segmental share, SWOT analysis, growth strategies, expansion techniques, and latest R&D initiatives are discussed in minute detail.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/oral-thin-film-drugs-market-6547